Atorvastatin half life
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Atorvastatin Half-Life: Pharmacokinetics and Influencing Factors
Introduction to Atorvastatin Pharmacokinetics
Atorvastatin is a widely used statin for lowering cholesterol levels by inhibiting HMG-CoA reductase. Understanding its pharmacokinetics, including its half-life, is crucial for optimizing its therapeutic use and managing potential drug interactions.
Half-Life of Atorvastatin
The half-life of atorvastatin varies depending on the study and the population being examined. In healthy human subjects, the half-life of atorvastatin is approximately 7 hours. However, other studies have reported a range of half-life values from 11 to 24 hours, indicating variability based on dosage and individual metabolism. In a study involving orange-winged Amazon parrots, the half-life was found to be around 5.96 hours, demonstrating species-specific differences.
Factors Influencing Atorvastatin Half-Life
Metabolism and Bioavailability
Atorvastatin undergoes extensive first-pass metabolism in the gut wall and liver, resulting in an oral bioavailability of about 14%. The drug is metabolized primarily by cytochrome P450 (CYP) 3A4, producing active metabolites that also contribute to its pharmacological effects. The half-life of atorvastatin can be significantly affected by co-administration with CYP3A4 inhibitors, such as itraconazole and clarithromycin, which can increase the half-life by approximately 60%.
Age and Gender
Age and gender also influence the pharmacokinetics of atorvastatin. Elderly individuals tend to have a longer half-life compared to younger adults, with studies showing a 36.2% increase in half-life in older adults. Women generally have a slightly shorter half-life compared to men, although the clinical significance of this difference remains unclear.
Food Intake
Food intake can affect the absorption rate of atorvastatin. A medium-fat meal decreases the peak concentration and increases the time to reach peak concentration, but it has little impact on the overall extent of absorption. This suggests that while food can delay the absorption, it does not significantly alter the half-life of the drug.
Drug Interactions
Atorvastatin's half-life can be extended when co-administered with drugs that inhibit its metabolism. For instance, cyclosporine significantly increases the systemic exposure of atorvastatin without altering its terminal half-life, likely due to inhibition of intestinal efflux and hepatic metabolism. Similarly, co-administration with other CYP3A4 inhibitors like verapamil and mibefradil can lead to substantial increases in atorvastatin's half-life and systemic exposure.
Conclusion
The half-life of atorvastatin is influenced by various factors including metabolism, age, gender, food intake, and drug interactions. Understanding these factors is essential for optimizing atorvastatin therapy and managing potential adverse effects. Clinicians should consider these variables when prescribing atorvastatin to ensure effective and safe cholesterol management.
Sources and full results
Most relevant research papers on this topic